SCHEMBL324228

SCHEMBL324228

O=C(OCc1ccccc1)N1CCc2ccccc2C1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 15/20 0.67
SIGMAR1 Q99720 15/20 0.67
NPC1 O15118 1/20 0.62
RAB9A P51151 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
ADRA2A P08913 3/20 0.59
ADRA2B P18089 3/20 0.59
HRH2 P25021 3/20 0.59
HTR2C P28335 3/20 0.59
HRH1 P35367 3/20 0.59
HRH3 Q9Y5N1 3/20 0.59
DRD3 P35462 2/20 0.59
HTR1A P08908 2/20 0.59
HTR2A P28223 2/20 0.59
HTR2B P41595 2/20 0.59
CHRM4 P08173 1/20 0.59
CHRM5 P08912 1/20 0.59
ADRA1D P25100 1/20 0.59
ADRA1A P35348 1/20 0.59
ADRA1B P35368 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15056469 0.92 NPC1 (0.67) TMEM97SIGMAR1NPC1RAB9AL3MBTL1
SCHEMBL324086 0.89 TMEM97 (0.64) TMEM97SIGMAR1NPC1RAB9AL3MBTL1
SCHEMBL1299903 0.88 TMEM97 (0.70) TMEM97SIGMAR1ADRA2AADRA2BHRH2
SCHEMBL30515329 0.88 TMEM97 (0.70) TMEM97SIGMAR1ADRA2AADRA2BHRH2
SCHEMBL30645345 0.88 TMEM97 (0.70) TMEM97SIGMAR1ADRA2AADRA2BHRH2
SCHEMBL3187484 0.88 TMEM97 (0.70) TMEM97SIGMAR1ADRA2AADRA2BHRH2
SCHEMBL4011213 0.86 TMEM97 (0.65) TMEM97SIGMAR1NPC1RAB9AL3MBTL1
SCHEMBL324836 0.86 PRMT5 (0.55) TMEM97SIGMAR1NPC1PRMT5WDR77
SCHEMBL19622378 0.86 TMEM97 (0.71) TMEM97SIGMAR1ADRA2AADRA2BHRH2
SCHEMBL18530311 0.86 TMEM97 (0.67) TMEM97SIGMAR1ADRA2AADRA2BHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119823124-A Compounds for targeted degradation of BRD9 C4医药公司 2025-04-15 CN disclosed
CN-115279370-B Compounds for targeted degradation of BRD9 C4医药公司 2025-01-10 CN disclosed
CN-116601150-A Fused bicyclic RAF inhibitors and methods of use thereof 爵士制药爱尔兰有限公司 2023-08-15 CN disclosed
WO-2023131122-A1 FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 劲方医药科技(上海)有限公司 2023-07-13 WO disclosed
CN-115279370-A Compounds for targeted degradation of BRD9 C4医药公司 2022-11-01 CN disclosed
WO-2022184152-A1 FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 劲方医药科技(上海)有限公司 2022-09-09 WO disclosed
CN-108368093-A The pyridin-3-yl acetogenin of inhibitor as human immunodeficiency virus replication VIIV保健英国第五有限公司 2018-08-03 CN disclosed
US-9920010-B2 CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2018-03-20 US disclosed
CN-105579450-B Novel indolizine compounds, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2017-12-12 CN disclosed
EP-1773786-B1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-04-26 EP disclosed
WO-2015145322-A1 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-10-01 WO disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 EP disclosed
US-8575158-B2 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2013-11-05 US disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 WO disclosed
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed
CN-1305470-A Amidine compounds JAPAN TOBACCO INC (JP) 2001-07-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 TMEM97 903/4885SIGMAR1 598/4885NPC1 2085/4885
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 TMEM97 984/4885SIGMAR1 351/4885NPC1 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.